Food and Drug Administration
Psychopharmacologic Drugs Advisory Committee Meeting
May 10, 2002
Briefing Document for Acamprosate 333gm Tablets
Calcium acetylhomotaurinate (acamprosate, Campral)
Briefing Information
Disclaimer
The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
Briefing Document for Acamprosate 333gm Tablets pdf
Clinical Background Materials doc pdf
Statistical Review and Evaluation htm doc pdf